Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402527 | 0.92 | LMNA (0.50) | ALDH1A1LMNANPSR1ACHEPTGS1 | |
| SCHEMBL5406373 | 0.90 | ALDH1A1 (0.50) | ALDH1A1LMNANPSR1ACHEPTGS1 | |
| SCHEMBL5404017 | 0.90 | NPSR1 (0.55) | ALDH1A1LMNANPSR1ACHEPTGS1 | |
| SCHEMBL5397992 | 0.89 | ALDH1A1 (0.48) | ALDH1A1LMNANPSR1ACHEPTGS1 | |
| SCHEMBL5418650 | 0.86 | PTGS1 (0.60) | ALDH1A1LMNANPSR1PTGS1PTGS2 | |
| SCHEMBL5407258 | 0.84 | CACNA1B (0.54) | ALDH1A1LMNANPSR1ACHEPTGS1 | |
| SCHEMBL5408875 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNANPSR1ACHEPTGS1 | |
| SCHEMBL5392578 | 0.83 | CACNA1B (0.55) | ALDH1A1LMNANPSR1ACHEPTGS1 | |
| SCHEMBL5402972 | 0.81 | ACHE (0.43) | ACHEPTGS1PTGS2MAPT | |
| SCHEMBL5156178 | 0.81 | NPSR1 (0.52) | ALDH1A1LMNANPSR1ACHEPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169782-B2 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-30 | — | — | US | claimed |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2004-09-09 | — | — | US | claimed |
| EP-1417187-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2004-05-12 | — | — | EP | claimed |
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE, S.A. | 2003-06-12 | — | — | US | claimed |
| WO-2003008398-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2003-01-30 | — | — | WO | claimed |
| US-7169782-B2 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-30 | — | — | US | disclosed |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2004-09-09 | — | — | US | disclosed |
| EP-1417187-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2004-05-12 | — | — | EP | disclosed |
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE, S.A. | 2003-06-12 | — | — | US | disclosed |
| WO-2003008398-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | CACNA1S, CACNA1I, CACNA1C | ALDH1A1 15/4885LMNA 730/4885NPSR1 873/4885 |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | CACNA1S, CACNA1I, NLN | ALDH1A1 26/4885LMNA 702/4885NPSR1 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.